Efficacy and safety of Velmanase alfa in the treatment of patients with alpha‐mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double‐blind, randomised, placebo‐controlled trial

Abstract

These findings support the utility of VA for the treatment of AM, with more evident benefit over time and when treatment is started in the paediatric age.